Plasma Amyloid Beta Species After a Single Solanezumab Infusion in Nondemented Individuals and Those With Mild Dementia of the Alzheimer's Type.
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2012
At a glance
- Drugs Solanezumab (Primary)
- Indications Alzheimer's disease
- Focus Biomarker; Pharmacodynamics
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.